NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
Mesoblast Ltd. MESO
10 fiscal years on record · USD · FY2024 reported · SEC filings only
Growth
USD 17.2M
Revenue, FY2024 · full 10-year series below
Revenue $M
Net income $M
FY2024 · Revenue 17.2 · Net income -102.1
Compound annual growth
Revenue compounded at −11.8% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−594 cents
lost on every revenue dollar
Operating margin
Net margin
FY2024 · Net -593.9%
ROE
Not available in our data for this period.
The 10-year record
10 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | · | · | · | · | · | · | · | · | · | · |
| EBITDA $B | · | · | · | · | · | · | · | · | · | · |
| Income tax $B | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 |
| Net income $B | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.1 | −0.0 |
| Free cash flow $B | −0.1 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | · | · | · | · |
| EPS, diluted $ | −0.08 | −0.09 | −0.11 | −0.13 | −0.16 | −0.15 | −0.18 | −0.08 | −0.19 | −0.01 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | · | · | · | · | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 38 reconciliationsAUDITED
Reconciled in 10 of 19 fiscal years. 54 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inoutside the United States — SEC code C3
Fiscal year endsJune 30
Data on record since2015